Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.48 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14018981 | 0.84 | NR1H2 (0.55) | NR1H2NR1H3GCKPGR | |
| SCHEMBL30628286 | 0.83 | ALDH1A1 (0.42) | — | |
| SCHEMBL3667501 | 0.83 | ALDH1A1 (0.42) | — | |
| SCHEMBL16566280 | 0.81 | HTT (0.61) | NR1H2NR1H3GCK | |
| SCHEMBL14018389 | 0.79 | PGR (0.60) | NR1H2NR1H3PGR | |
| SCHEMBL29486889 | 0.79 | NR1H2 (0.48) | NR1H2NR1H3GCKRXRAPGR | |
| SCHEMBL22918295 | 0.79 | NR1H2 (0.48) | NR1H2NR1H3GCKRXRAPGR | |
| SCHEMBL8738326 | 0.79 | HTT (0.64) | NR1H2NR1H3GCKPGR | |
| SCHEMBL30148759 | 0.79 | ALDH1A1 (0.46) | — | |
| SCHEMBL3841098 | 0.79 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9399646-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | WYETH LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885GCK 1950/4885 |
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | NR1H2 2/4885NR1H3 3/4885GCK 1244/4885 |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | NR1H2 19/4885NR1H3 31/4885GCK 3917/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | NR1H2 19/4885NR1H3 31/4885GCK 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.